SANOFI-ADR (SNY) Fundamental Analysis & Valuation

NASDAQ:SNY • US80105N1054

43.97 USD
0 (0%)
Last: Mar 11, 2026, 03:10 PM

This SNY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

SNY gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. SNY has an excellent profitability rating, but there are some minor concerns on its financial health. SNY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. SNY also has an excellent dividend rating. These ratings could make SNY a good candidate for value and dividend investing.


Dividend Valuation Growth Profitability Health

8

1. SNY Profitability Analysis

1.1 Basic Checks

  • In the past year SNY was profitable.
  • SNY had a positive operating cash flow in the past year.
  • Each year in the past 5 years SNY has been profitable.
  • In the past 5 years SNY always reported a positive cash flow from operatings.
SNY Yearly Net Income VS EBIT VS OCF VS FCFSNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

1.2 Ratios

  • SNY's Return On Assets of 9.85% is amongst the best of the industry. SNY outperforms 91.19% of its industry peers.
  • The Return On Equity of SNY (17.49%) is better than 89.12% of its industry peers.
  • SNY's Return On Invested Capital of 13.76% is amongst the best of the industry. SNY outperforms 93.78% of its industry peers.
  • SNY had an Average Return On Invested Capital over the past 3 years of 7.41%. This is significantly below the industry average of 13.09%.
  • The last Return On Invested Capital (13.76%) for SNY is above the 3 year average (7.41%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 9.85%
ROE 17.49%
ROIC 13.76%
ROA(3y)4.87%
ROA(5y)5.28%
ROE(3y)8.47%
ROE(5y)9.13%
ROIC(3y)7.41%
ROIC(5y)7.45%
SNY Yearly ROA, ROE, ROICSNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • SNY has a Profit Margin of 17.71%. This is amongst the best in the industry. SNY outperforms 91.19% of its industry peers.
  • SNY's Profit Margin has declined in the last couple of years.
  • SNY has a better Operating Margin (23.28%) than 90.16% of its industry peers.
  • In the last couple of years the Operating Margin of SNY has grown nicely.
  • The Gross Margin of SNY (72.55%) is better than 79.27% of its industry peers.
  • SNY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 23.28%
PM (TTM) 17.71%
GM 72.55%
OM growth 3Y-0.84%
OM growth 5Y1.78%
PM growth 3Y-3.21%
PM growth 5Y-12.66%
GM growth 3Y1.06%
GM growth 5Y1.33%
SNY Yearly Profit, Operating, Gross MarginsSNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

5

2. SNY Health Analysis

2.1 Basic Checks

  • SNY has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, SNY has less shares outstanding
  • SNY has less shares outstanding than it did 5 years ago.
  • SNY has a worse debt/assets ratio than last year.
SNY Yearly Shares OutstandingSNY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
SNY Yearly Total Debt VS Total AssetsSNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • The Debt to FCF ratio of SNY is 1.86, which is an excellent value as it means it would take SNY, only 1.86 years of fcf income to pay off all of its debts.
  • SNY has a better Debt to FCF ratio (1.86) than 95.34% of its industry peers.
  • SNY has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
  • SNY has a Debt to Equity ratio of 0.22. This is comparable to the rest of the industry: SNY outperforms 43.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 1.86
Altman-Z N/A
ROIC/WACC1.76
WACC7.84%
SNY Yearly LT Debt VS Equity VS FCFSNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

2.3 Liquidity

  • A Current Ratio of 1.09 indicates that SNY should not have too much problems paying its short term obligations.
  • SNY has a Current ratio of 1.09. This is amonst the worse of the industry: SNY underperforms 80.31% of its industry peers.
  • SNY has a Quick Ratio of 1.09. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
  • SNY's Quick ratio of 1.09 is on the low side compared to the rest of the industry. SNY is outperformed by 74.61% of its industry peers.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.09
SNY Yearly Current Assets VS Current LiabilitesSNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

4

3. SNY Growth Analysis

3.1 Past

  • SNY shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.82%.
  • Measured over the past 5 years, SNY shows a small growth in Earnings Per Share. The EPS has been growing by 5.58% on average per year.
  • Looking at the last year, SNY shows a small growth in Revenue. The Revenue has grown by 5.29% in the last year.
  • SNY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.57% yearly.
EPS 1Y (TTM)1.82%
EPS 3Y-1.77%
EPS 5Y5.58%
EPS Q2Q%16.79%
Revenue 1Y (TTM)5.29%
Revenue growth 3Y0.97%
Revenue growth 5Y4.57%
Sales Q2Q%7%

3.2 Future

  • SNY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.49% yearly.
  • The Revenue is expected to grow by 5.29% on average over the next years.
EPS Next Y8.41%
EPS Next 2Y6.95%
EPS Next 3Y8.43%
EPS Next 5Y8.49%
Revenue Next Year6.58%
Revenue Next 2Y6.19%
Revenue Next 3Y5.8%
Revenue Next 5Y5.29%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SNY Yearly Revenue VS EstimatesSNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B 50B
SNY Yearly EPS VS EstimatesSNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4 5

7

4. SNY Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 9.56 indicates a reasonable valuation of SNY.
  • Based on the Price/Earnings ratio, SNY is valued cheaply inside the industry as 92.23% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 26.25, SNY is valued rather cheaply.
  • The Price/Forward Earnings ratio is 8.82, which indicates a very decent valuation of SNY.
  • Based on the Price/Forward Earnings ratio, SNY is valued cheaply inside the industry as 90.67% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of SNY to the average of the S&P500 Index (24.39), we can say SNY is valued rather cheaply.
Industry RankSector Rank
PE 9.56
Fwd PE 8.82
SNY Price Earnings VS Forward Price EarningsSNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • SNY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SNY is cheaper than 93.26% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.36
EV/EBITDA N/A
SNY Per share dataSNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • SNY's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of SNY may justify a higher PE ratio.
PEG (NY)1.14
PEG (5Y)1.71
EPS Next 2Y6.95%
EPS Next 3Y8.43%

7

5. SNY Dividend Analysis

5.1 Amount

  • SNY has a Yearly Dividend Yield of 5.30%, which is a nice return.
  • Compared to an average industry Dividend Yield of 0.70, SNY pays a better dividend. On top of this SNY pays more dividend than 97.41% of the companies listed in the same industry.
  • SNY's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 5.3%

5.2 History

  • The dividend of SNY has a limited annual growth rate of 4.30%.
  • SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
  • The dividend of SNY decreased in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
SNY Yearly Dividends per shareSNY Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6

5.3 Sustainability

  • SNY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DPN/A
EPS Next 2Y6.95%
EPS Next 3Y8.43%
SNY Yearly Income VS Free CF VS DividendSNY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

SNY Fundamentals: All Metrics, Ratios and Statistics

SANOFI-ADR

NASDAQ:SNY (3/11/2026, 3:10:54 PM)

43.97

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-29
Earnings (Next)04-23
Inst Owners46.23%
Inst Owner Change-1.94%
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap106.20B
Revenue(TTM)70.49B
Net Income(TTM)12.49B
Analysts76
Price Target57.52 (30.82%)
Short Float %0.37%
Short Ratio2.03
Dividend
Industry RankSector Rank
Dividend Yield 5.3%
Yearly Dividend2.21
Dividend Growth(5Y)4.3%
DPN/A
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.22%
Min EPS beat(2)4.58%
Max EPS beat(2)5.86%
EPS beat(4)3
Avg EPS beat(4)3.54%
Min EPS beat(4)-2.29%
Max EPS beat(4)6.02%
EPS beat(8)6
Avg EPS beat(8)4.07%
EPS beat(12)8
Avg EPS beat(12)3.12%
EPS beat(16)11
Avg EPS beat(16)3.47%
Revenue beat(2)0
Avg Revenue beat(2)-1.69%
Min Revenue beat(2)-2.08%
Max Revenue beat(2)-1.3%
Revenue beat(4)0
Avg Revenue beat(4)-1.33%
Min Revenue beat(4)-2.08%
Max Revenue beat(4)-0.63%
Revenue beat(8)2
Avg Revenue beat(8)-0.61%
Revenue beat(12)2
Avg Revenue beat(12)-1.44%
Revenue beat(16)6
Avg Revenue beat(16)14.04%
PT rev (1m)-2.24%
PT rev (3m)-7.57%
EPS NQ rev (1m)0.19%
EPS NQ rev (3m)6.49%
EPS NY rev (1m)0.44%
EPS NY rev (3m)-0.61%
Revenue NQ rev (1m)-0.6%
Revenue NQ rev (3m)-1.7%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)-0.4%
Valuation
Industry RankSector Rank
PE 9.56
Fwd PE 8.82
P/S 1.29
P/FCF 8.36
P/OCF 8.36
P/B 1.28
P/tB 23.91
EV/EBITDA N/A
EPS(TTM)4.6
EY10.46%
EPS(NY)4.98
Fwd EY11.34%
FCF(TTM)5.26
FCFY11.97%
OCF(TTM)5.26
OCFY11.97%
SpS33.98
BVpS34.4
TBVpS1.84
PEG (NY)1.14
PEG (5Y)1.71
Graham Number59.67
Profitability
Industry RankSector Rank
ROA 9.85%
ROE 17.49%
ROCE 16.67%
ROIC 13.76%
ROICexc 14.92%
ROICexgc 58.3%
OM 23.28%
PM (TTM) 17.71%
GM 72.55%
FCFM 15.49%
ROA(3y)4.87%
ROA(5y)5.28%
ROE(3y)8.47%
ROE(5y)9.13%
ROIC(3y)7.41%
ROIC(5y)7.45%
ROICexc(3y)8.06%
ROICexc(5y)8.26%
ROICexgc(3y)31.82%
ROICexgc(5y)35.77%
ROCE(3y)8.99%
ROCE(5y)9.04%
ROICexgc growth 3Y-8.07%
ROICexgc growth 5Y1.04%
ROICexc growth 3Y-0.36%
ROICexc growth 5Y3.93%
OM growth 3Y-0.84%
OM growth 5Y1.78%
PM growth 3Y-3.21%
PM growth 5Y-12.66%
GM growth 3Y1.06%
GM growth 5Y1.33%
F-Score5
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 1.86
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality 87.43%
Current Ratio 1.09
Quick Ratio 1.09
Altman-Z N/A
F-Score5
WACC7.84%
ROIC/WACC1.76
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)127.25%
Profit Quality(5y)123.49%
High Growth Momentum
Growth
EPS 1Y (TTM)1.82%
EPS 3Y-1.77%
EPS 5Y5.58%
EPS Q2Q%16.79%
EPS Next Y8.41%
EPS Next 2Y6.95%
EPS Next 3Y8.43%
EPS Next 5Y8.49%
Revenue 1Y (TTM)5.29%
Revenue growth 3Y0.97%
Revenue growth 5Y4.57%
Sales Q2Q%7%
Revenue Next Year6.58%
Revenue Next 2Y6.19%
Revenue Next 3Y5.8%
Revenue Next 5Y5.29%
EBIT growth 1Y7.73%
EBIT growth 3Y0.11%
EBIT growth 5Y6.43%
EBIT Next Year28.69%
EBIT Next 3Y14.49%
EBIT Next 5Y9.74%
FCF growth 1Y85.47%
FCF growth 3Y9.46%
FCF growth 5Y15.4%
OCF growth 1Y20.22%
OCF growth 3Y1.22%
OCF growth 5Y8.03%

SANOFI-ADR / SNY FAQ

What is the fundamental rating for SNY stock?

ChartMill assigns a fundamental rating of 6 / 10 to SNY.


Can you provide the valuation status for SANOFI-ADR?

ChartMill assigns a valuation rating of 7 / 10 to SANOFI-ADR (SNY). This can be considered as Undervalued.


How profitable is SANOFI-ADR (SNY) stock?

SANOFI-ADR (SNY) has a profitability rating of 8 / 10.


What are the PE and PB ratios of SANOFI-ADR (SNY) stock?

The Price/Earnings (PE) ratio for SANOFI-ADR (SNY) is 9.56 and the Price/Book (PB) ratio is 1.28.